ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors

The market for antibody drug conjugates, or ADCs, is heating up, and the FDA on Monday sought to offer some guidance based on its past experience with ADC development programs in oncology by offering new draft guidance on clinical pharmacology considerations for ADCs in particular.